← Back to Search

Tyrosine Kinase Inhibitor

TKIs for Dementia

Phase 1
Waitlist Available
Led By Sheldon Jordan, MD
Research Sponsored by Neurological Associates of West Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Cognitive decline with mild cognitive impairment (Clinical Dementia Rating Stage 0.5) through moderate dementia (CDR Stages 1 and 2)
Be older than 18 years old
Must not have
Advanced stages of any terminal illness or any active cancer that requires chemotherapy
Subjects with contraindications for lumbar puncture, such as bleeding abnormalities, use of anticoagulant medications, and local skin or spine abnormalities
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Summary

This trial is designed to evaluate the tolerability and potential efficacy of tyrosine kinase inhibitors in patients with mild cognitive impairment or dementia. Baseline and outcome measures utilize validated tests that are appropriate for repeated measures. The study population is sufficiently broad and the conditions of interest are sufficiently prevalent so that recruitment of the projected numbers of subjects is not a limiting factor.

Who is the study for?
This trial is for people with mild to moderate dementia or cognitive decline, who can handle a lumbar puncture and don't have allergies to bosutinib. It's not for those with reversible cognitive issues, severe illnesses like advanced cancer, kidney or liver problems, heart rhythm issues, blood disorders, recent thrombosis, pregnant or breastfeeding women, and those unable to consent.
What is being tested?
The study tests the drug bosutinib on patients with dementia. Starting at 100 mg daily and potentially increasing monthly up to 300 mg if tolerated without serious side effects. The goal is to see how well it works over time using brain scans and memory tests that are reliable and widely available.
What are the potential side effects?
Possible side effects of bosutinib include allergic reactions for those sensitive to it. As doses increase from 100 mg up to 300 mg daily if tolerated, monitoring will be done using CTCAE Version 5.0 guidelines; dose adjustments may occur based on severity of any adverse reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have mild to moderate memory or thinking problems.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have an advanced terminal illness or cancer needing chemotherapy.
Select...
I cannot have a lumbar puncture due to bleeding issues, medication, or spine problems.
Select...
I have liver problems.
Select...
I have had blood clots in my heart, brain, or limbs.
Select...
I have kidney problems.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Therapeutic procedure

Side effects data

From 2014 Phase 2 trial • 36 Patients • NCT01331291
73%
lymphocyte count decreased
55%
fatigue
45%
nausea
45%
elevated alanine aminotransferase
36%
seizure
36%
hypophosphatemia
36%
maculo-papular rash
27%
diarrhea
27%
rash
18%
lung infection
18%
elevated aspartate aminotransferase
9%
fall
9%
dizziness
9%
vomiting
9%
headache
9%
cerebral edema
9%
cellulitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Combined Arms

Trial Design

1Treatment groups
Experimental Treatment
Group I: Bosutinib Treatment ArmExperimental Treatment1 Intervention
Subjects will be administered the initial dose of bosutinib, with dosage progressively increased over the course of the study. The initial dose of bosutinib is 100 mg tablet, once per day. The dose will be increased as tolerated up to 300 mg per day. The dose will be increased by 100 mg each month if the lower dose is tolerated without significant side effects. That is to say, the subject will take 100 mg/day every day for the first month, 200 mg/day every day for the second month, and 300 mg/day every day for the third month and for the remainder of the study, provided that adverse reactions do not prohibit continuation at this dosage. Stopping and dose reduction rules for reported adverse reactions have been taken from the package insert of bosutinib. The duration of treatment is 1 year.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bosutinib
FDA approved

Find a Location

Who is running the clinical trial?

Neurological Associates of West Los AngelesLead Sponsor
25 Previous Clinical Trials
3,810 Total Patients Enrolled
3 Trials studying Dementia
423 Patients Enrolled for Dementia
PfizerIndustry Sponsor
4,625 Previous Clinical Trials
14,284,044 Total Patients Enrolled
7 Trials studying Dementia
3,078 Patients Enrolled for Dementia
Sheldon Jordan, MDPrincipal InvestigatorNeurological Associates of West Los Angeles
12 Previous Clinical Trials
2,440 Total Patients Enrolled

Media Library

bosutinib (Tyrosine Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT02921477 — Phase 1
Dementia Research Study Groups: Bosutinib Treatment Arm
Dementia Clinical Trial 2023: bosutinib Highlights & Side Effects. Trial Name: NCT02921477 — Phase 1
bosutinib (Tyrosine Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02921477 — Phase 1
~17 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top